Abstract: A method for controlling a suspension system is disclosed. The method includes obtaining a first group of signals and a second group of signals; determining whether a trigger condition is met; determining an adjustment signal for adjusting the suspension system based on related signals of the suspension system, in response to the trigger condition being met; using the adjustment signal on the suspension system; the first group of signals being signals related to a comfort braking control system and the second group of signals being signals related to driving expectations. A system for controlling a suspension system and a suspension control system are also disclosed.

Abstract: The invention relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.

Abstract: The invention relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.

Abstract: Compounds of the formulas which are useful as colony stimulating factor-1 receptor inhibitors (“CSF-1R inhibitors”).

Abstract: Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).

Abstract: The present invention disclosed an application of an antisense oligonucleotide targeting a PBX1 promoter region G-quadruplex in a preparation of a medicine for treating melanoma. The medicine for treating melanoma has one or more of following uses: inhibiting the proliferation of melanoma cell; inhibiting the migration of melanoma cell; inhibiting the invasion of melanoma cell; inhibiting the growth of melanoma; and inhibiting the lung metastasis of melanoma. The identification of the antisense oligonucleotide targeting the PBX1 promoter region G-quadruplex provided by the present invention provides a new drug target and new treatment methods and ideas for the development of a new generation of inhibiting melanoma medicines.

Abstract: Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).

Abstract: Provided is an isolated monoclonal antibody or an antigen-binding portion thereof that specifically binds human CD40. A nucleic acid molecule encoding the antibody or antigen-binding portion thereof, an expression vector, a host cell and a method for expressing the antibody or the antigen-binding portion thereof are also provided. An immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody or antigen-binding portion thereof, as well as a treatment method using the same are further provided.

Abstract: Provided herein are compounds and compositions thereof for modulating bis-phosphoglycerate mutase (BPGM) for treating sickle cell disease.

Abstract: Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).

Abstract: Compounds of the formulas which are useful as colony stimulating factor-1 receptor inhibitors (“CSF-1R inhibitors”).

Abstract: The present invention provides a storage and sorting method and apparatus, a control device and a storage medium, and relates to the field of logistics. The storing and sorting apparatus of the present disclosure includes: a conveying device configured to convey articles; and at least one storage device, wherein the storage device is located over the conveying device, and is configured to obtain and store the articles conveyed on the conveying device in a storage phase, and release the stored articles to the conveying device in a sorting phase.

Abstract: Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).

Abstract: Compounds of the formulas which are useful as colony stimulating factor-1 receptor inhibitors (“CSF-1R inhibitors”).

Abstract: A method is disclosed for determining flow measurement values of a Coriolis mass flowmeter in the presence of a two-phase flow of a two-phase medium having a gas phase and the subsequent presence of a single-phase flow of a single-phase medium not having a gas phase. The method includes: detecting a start time of a two-phase measurement interval at an onset of the two-phase flow; detecting an end time of the two-phase measurement interval at an end of the presence of the two-phase flow; determining and at least partially storing two-phase flow measurement values of the two-phase flow; determining at least one state variable of the single-phase medium; determining subsequently corrected two-phase flow measurement values as at least indirect input variables of a correction calculation; and outputting the corrected two-phase flow measurement values as individual values or as part of a cumulative flow measurement value.

Abstract: Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).

Abstract: An information push method includes: acquiring a monitoring image captured by a camera; identifying a target group contained in the monitoring image; performing a group relationship recognition on the target group according to attribute data of the target group to recognize a group relationship type of the target group; and pushing a recommendation information to at least one designated terminal corresponding to the target group based on the group relationship type. An information push device and an information push system are also provided.

Abstract: An information push method includes: acquiring a monitoring image captured by a camera; identifying a target group contained in the monitoring image; performing a group relationship recognition on the target group according to attribute data of the target group to recognize a group relationship type of the target group; and pushing a recommendation information to at least one designated terminal corresponding to the target group based on the group relationship type. An information push device and an information push system are also provided.